Melanoma

Novel design enhances GM-CSF tumor vaccine

Published in Cancer Weekly, October 15th, 2002

by Sonia Nichols, senior medical writer - A cancer vaccine now undergoing clinical evaluation might be enhanced by simply changing the form in which it is presented.

Granulocyte-macrophage colony-stimulating factor (GM-CSF) tumor vaccines have shown promise for their ability to stimulate immune system response against cancer. Officials at the Immune Response Corporation in Carlsbad, California, recently announced they have enhanced GM-CSF tumor vaccine cancer fighting ability by expressing GM-CSF as a membrane bound form (mbGM-CSF). According to them, the membrane bound form of GM-CSF boosts immunogenicity.

The premise behind the novel design is...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2002-10-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry